Temat: "Adenocarcinoma of Lung" - OpacWWW

Skocz do pozycji: 1 1.

Tytuł :: CYLD expression in dendritic cells involved in the immunoregulation of pulmonary adenocarcinoma via NF-κB pathway.
Autorzy :: Yu Q; Department of Radiology, Fujian Provincial Hospital, Provincial Clinical College of Fujian Medical University, Fuzhou, China.
Lei Y; Department of Thoracic Surgery, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Huang Y; Department of Thoracic Surgery, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Zhang J; Department of Thoracic Surgery, Fujian Provincial Hospital, Provincial Clinical College of Fujian Medical University, Fuzhou, China.
Chen Y; Department of Thoracic Surgery, Fujian Provincial Hospital, Provincial Clinical College of Fujian Medical University, Fuzhou, China.
Chen K; Department of Thoracic Surgery, Fujian Provincial Hospital, Provincial Clinical College of Fujian Medical University, Fuzhou, China.
Lin J; Department of Thoracic Surgery, Fujian Provincial Hospital, Provincial Clinical College of Fujian Medical University, Fuzhou, China.
Sun S; Department of Thoracic Surgery, Fujian Provincial Hospital, Provincial Clinical College of Fujian Medical University, Fuzhou, China.
Lin X; Department of Thoracic Surgery, Fujian Provincial Hospital, Provincial Clinical College of Fujian Medical University, Fuzhou, China.; Pokaż więcej
Źródło :: Artificial cells, nanomedicine, and biotechnology [Artif Cells Nanomed Biotechnol] 2020 Dec; Vol. 48 (1), pp. 137-142.
Typ publikacji :: Journal Article
MeSH Terms :: Immunomodulation*
Adenocarcinoma of Lung/*immunology
Adenocarcinoma of Lung/*pathology
Dendritic Cells/*metabolism
Deubiquitinating Enzyme CYLD/*metabolism
NF-kappa B/*metabolism
Signal Transduction/*immunology
Adenocarcinoma of Lung/genetics ; Adenocarcinoma of Lung/metabolism ; Animals ; CD4-Positive T-Lymphocytes/cytology ; Cell Proliferation ; Dendritic Cells/immunology ; Deubiquitinating Enzyme CYLD/deficiency ; Deubiquitinating Enzyme CYLD/genetics ; Disease Progression ; Gene Knockout Techniques ; Mice
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 2 2.

Tytuł :: Lung cancer pathogenesis and poor response to therapy were dependent on driver oncogenic mutations.
Autorzy :: Sun X; Department of Thoracic Surgery, the Second Department of Thoracic Surgery, Department of Thoracic Surgery and Oncology, Cancer Center, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an City, Shaanxi Province 710061, China. Electronic address: .
Li K; Department of Thoracic Surgery, the Second Department of Thoracic Surgery, Department of Thoracic Surgery and Oncology, Cancer Center, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an City, Shaanxi Province 710061, China.
Zhao R; Department of Thoracic Surgery, the Second Department of Thoracic Surgery, Department of Thoracic Surgery and Oncology, Cancer Center, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an City, Shaanxi Province 710061, China.
Sun Y; Department of Anesthesiology and Operation, Operating Centre, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an City, Shaanxi Province 710061, China.
Xu J; Department of Thoracic Surgery, the Second Department of Thoracic Surgery, Department of Thoracic Surgery and Oncology, Cancer Center, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an City, Shaanxi Province 710061, China; Department of General Surgery, the People's Hospital of Shanyang County, Luonan City, Shaanxi Province 726411, China.
Peng ZY; Department of Thoracic Surgery, the Second Department of Thoracic Surgery, Department of Thoracic Surgery and Oncology, Cancer Center, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an City, Shaanxi Province 710061, China.
Song RD; Department of Thoracic Surgery, the Second Department of Thoracic Surgery, Department of Thoracic Surgery and Oncology, Cancer Center, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an City, Shaanxi Province 710061, China.
Ren H; Department of Thoracic Surgery, the Second Department of Thoracic Surgery, Department of Thoracic Surgery and Oncology, Cancer Center, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an City, Shaanxi Province 710061, China.
Tang SC; University of Mississippi Medical Center, Cancer Center and Research Institute, 2500 North State Street, Jackson, MS 39216, USA. Electronic address: .; Pokaż więcej
Źródło :: Life sciences [Life Sci] 2021 Jan 15; Vol. 265, pp. 118797. Date of Electronic Publication: 2020 Dec 04.
Typ publikacji :: Journal Article
MeSH Terms :: Adenocarcinoma of Lung/*genetics
Carcinogenesis/*genetics
Lung Neoplasms/*genetics
Mutation/*genetics
Oncogenes/*genetics
Smoking/*genetics
Adenocarcinoma of Lung/pathology ; Adenocarcinoma of Lung/therapy ; Aged ; Biomarkers, Tumor/genetics ; Carcinogenesis/drug effects ; Carcinogenesis/pathology ; Female ; Humans ; Lung Neoplasms/pathology ; Lung Neoplasms/therapy ; Male ; Middle Aged ; Mutation/drug effects ; Oncogenes/drug effects ; Smoking/pathology ; Smoking/therapy ; Survival Rate/trends ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 3 3.

Tytuł :: Early Blood-based Liquid Biopsy in Patients with Treatment-naïve Metastatic Adenocarcinoma of the Lung: A Case Series.
Autorzy :: Peled M; Institute of Pulmonary Medicine, Sheba Medical Center, Tel Hashomer, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Bar J; Department of Radiation Oncology, Sheba Medical Center, Tel Hashomer, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Avni L; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel.
Chatterji S; Institute of Pulmonary Medicine, Sheba Medical Center, Tel Hashomer, Israel.
Somech D; Institute of Pulmonary Medicine, Sheba Medical Center, Tel Hashomer, Israel.
Dvir A; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel.
Soussan-Gutman L; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel.
Onn A; Institute of Pulmonary Medicine, Sheba Medical Center, Tel Hashomer, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Pokaż więcej
Źródło :: The Israel Medical Association journal : IMAJ [Isr Med Assoc J] 2020 Dec; Vol. 22 (12), pp. 784-787.
Typ publikacji :: Journal Article
MeSH Terms :: Adenocarcinoma of Lung/*diagnosis
Lung Neoplasms/*diagnosis
Acrylamides/therapeutic use ; Adenocarcinoma of Lung/blood ; Adenocarcinoma of Lung/drug therapy ; Adenocarcinoma of Lung/genetics ; Aged ; Aged, 80 and over ; Aniline Compounds/therapeutic use ; Antineoplastic Agents/therapeutic use ; Biomarkers, Tumor/blood ; Carbazoles/therapeutic use ; Carcinoma, Non-Small-Cell Lung/blood ; Carcinoma, Non-Small-Cell Lung/diagnosis ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Crizotinib/therapeutic use ; DNA, Neoplasm/blood ; Female ; Genotyping Techniques ; Humans ; Lung Neoplasms/blood ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Male ; Middle Aged ; Piperidines/therapeutic use ; Prospective Studies
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 4 4.

Tytuł :: Management of Ground-Glass Opacities in the Lung Cancer Spectrum.
Autorzy :: Zhang Y; Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Institute of Thoracic Oncology, Fudan University, Shanghai, China; State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Fu F; Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Institute of Thoracic Oncology, Fudan University, Shanghai, China; State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Chen H; Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Institute of Thoracic Oncology, Fudan University, Shanghai, China; State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. Electronic address: .; Pokaż więcej
Źródło :: The Annals of thoracic surgery [Ann Thorac Surg] 2020 Dec; Vol. 110 (6), pp. 1796-1804. Date of Electronic Publication: 2020 Jun 07.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :: Adenocarcinoma of Lung/*diagnostic imaging
Adenocarcinoma of Lung/*pathology
Lung Neoplasms/*diagnostic imaging
Lung Neoplasms/*pathology
Adenocarcinoma of Lung/therapy ; Early Detection of Cancer ; Humans ; Lung Neoplasms/therapy ; Tomography, X-Ray Computed
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 5 5.

Tytuł :: KANK1 regulates paclitaxel resistance in lung adenocarcinoma A549 cells.
Autorzy :: Pu J; School of Life Sciences, Northwest University, Xi'an, China.; Department of Cardiovascular Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Shen J; School of Life Sciences, Northwest University, Xi'an, China.
Zhong Z; School of Life Sciences, Northwest University, Xi'an, China.
Yanling M; School of Life Sciences, Northwest University, Xi'an, China.
Gao J; Department of Cardiovascular Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.; Pokaż więcej
Źródło :: Artificial cells, nanomedicine, and biotechnology [Artif Cells Nanomed Biotechnol] 2020 Dec; Vol. 48 (1), pp. 639-647.
Typ publikacji :: Journal Article
MeSH Terms :: Adaptor Proteins, Signal Transducing/*genetics
Adenocarcinoma of Lung/*drug therapy
Antineoplastic Agents, Phytogenic/*therapeutic use
Cytoskeletal Proteins/*genetics
Drug Resistance, Neoplasm/*genetics
Lung Neoplasms/*drug therapy
Paclitaxel/*therapeutic use
A549 Cells ; Adaptor Proteins, Signal Transducing/metabolism ; Adenocarcinoma of Lung/genetics ; Adenocarcinoma of Lung/pathology ; Antineoplastic Agents, Phytogenic/pharmacology ; Apoptosis/genetics ; Cell Line, Tumor ; Cell Movement/genetics ; Cytoskeletal Proteins/metabolism ; DNA Methylation ; Disease-Free Survival ; Drug Resistance, Neoplasm/drug effects ; Gene Expression Regulation, Neoplastic ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Paclitaxel/pharmacology ; Tumor Suppressor Proteins/genetics ; Tumor Suppressor Proteins/metabolism
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 6 6.

Tytuł :: High fibrinogen-albumin ratio index predicts poor prognosis for lung adenocarcinoma patients undergoing epidermal growth factor receptor-tyrosine kinase inhibitor treatments.
Autorzy :: Zhao X; Department of Oncology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zhang N
Zhang H
Liu P
Ma J
Hu C
Liu X
Hou T; Pokaż więcej
Źródło :: Medicine [Medicine (Baltimore)] 2020 Nov 13; Vol. 99 (46), pp. e23150.
Typ publikacji :: Journal Article
MeSH Terms :: Adenocarcinoma of Lung*/blood
Adenocarcinoma of Lung*/drug therapy
Adenocarcinoma of Lung*/genetics
Adenocarcinoma of Lung*/pathology
Carcinoma, Non-Small-Cell Lung*/blood
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/pathology
ErbB Receptors/*genetics
Fibrinogen/*analysis
Protein Kinase Inhibitors/*therapeutic use
Serum Albumin, Human/*analysis
Biomarkers/blood ; Blood Cell Count/methods ; Female ; Humans ; Male ; Middle Aged ; Mutation ; Predictive Value of Tests ; Prognosis ; Progression-Free Survival
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 7 7.

Tytuł :: A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib: A case report.
Autorzy :: Guo J; Department of Internal Medicine-Oncology, Xingtai People's Hospital, Xingtai, Hebei Province, China.
Shi J; OrigiMed Co. Ltd, Shanghai, China.
Yao M; OrigiMed Co. Ltd, Shanghai, China.
Jin Y; Department of Oncology, Xingtai People's Hospital, Xingtai, Hebei Province.
Liu D; Department of Oncology, Xingtai People's Hospital, Xingtai, Hebei Province.
Liu W; OrigiMed Co. Ltd, Shanghai, China.
Wang K; OrigiMed Co. Ltd, Shanghai, China.
Jiang D; Department of Medical Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China.s.; Pokaż więcej
Źródło :: Medicine [Medicine (Baltimore)] 2020 Nov 06; Vol. 99 (45), pp. e22631.
Typ publikacji :: Case Reports; Journal Article
MeSH Terms :: Adenocarcinoma of Lung/*drug therapy
Adenocarcinoma of Lung/*genetics
Anaplastic Lymphoma Kinase/*genetics
Antineoplastic Agents/*therapeutic use
Crizotinib/*therapeutic use
Cyclin-Dependent Kinases/*genetics
Oncogene Proteins, Fusion/*genetics
Adenocarcinoma of Lung/diagnostic imaging ; Disease Progression ; Female ; Humans ; Middle Aged ; Tomography, X-Ray Computed
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 8 8.

Tytuł :: In vivo miRNA knockout screening identifies miR-190b as a novel tumor suppressor.
Autorzy :: Hong H; Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Yao S; State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences; Shanghai, China.; University of Chinese Academy of Sciences, Beijing, China.
Zhang Y; BIOPIC and School of Life Sciences, Peking University, Beijing, China.
Ye Y; State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences; Shanghai, China.; School of Life Science and Technology, Shanghai Tech University, Shanghai, China.
Li C; Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, School of Life Sciences, Peking University, Beijing, China.; Center for Statistical Science, Center for Bioinformatics, Peking University, Beijing, China.
Hu L; State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences; Shanghai, China.
Sun Y; Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Huang HY; State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences; Shanghai, China.
Ji H; State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences; Shanghai, China.; University of Chinese Academy of Sciences, Beijing, China.; School of Life Science and Technology, Shanghai Tech University, Shanghai, China.; Pokaż więcej
Źródło :: PLoS genetics [PLoS Genet] 2020 Nov 02; Vol. 16 (11), pp. e1009168. Date of Electronic Publication: 2020 Nov 02 (Print Publication: 2020).
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Adenocarcinoma of Lung/*genetics
Cell Cycle Proteins/*genetics
Lung Neoplasms/*genetics
MicroRNAs/*metabolism
Adenocarcinoma of Lung/mortality ; Adenocarcinoma of Lung/pathology ; Animals ; Carcinogenesis/genetics ; Cell Line, Tumor ; Computational Biology ; Datasets as Topic ; Disease Models, Animal ; Down-Regulation ; Gene Expression Regulation, Neoplastic ; Genes, Tumor Suppressor ; HEK293 Cells ; Humans ; Kaplan-Meier Estimate ; Lung/pathology ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Mice ; Mice, Knockout ; MicroRNAs/genetics ; Neoplasm Staging ; Proto-Oncogene Proteins p21(ras)/genetics ; Tumor Suppressor Protein p53/genetics
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 9 9.

Tytuł :: Breast metastasis from EGFR/ALK negative lung adenocarcinoma: A case report.
Autorzy :: Cao L; Department of Medical Oncology.
Lv L; Department of Oncology Surgery, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China.; Pokaż więcej
Źródło :: Medicine [Medicine (Baltimore)] 2020 Dec 04; Vol. 99 (49), pp. e23503.
Typ publikacji :: Case Reports; Journal Article
MeSH Terms :: Adenocarcinoma of Lung/*secondary
Breast Neoplasms/*secondary
Lung Neoplasms/*pathology
Adenocarcinoma of Lung/pathology ; Breast/pathology ; Fatal Outcome ; Female ; Humans ; Middle Aged
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 10 10.

Tytuł :: Incidental Detection of Lung Adenocarcinoma Presenting as an Anterior Mediastinal Mass on 18F-Fluciclovine PET/CT in a Patient With Primary Prostate Cancer.
Autorzy :: Abiodun-Ojo OA; From the Departments of Radiology and Imaging Sciences.
Akintayo AA; From the Departments of Radiology and Imaging Sciences.
Sica GL; Pathology and Laboratory Medicine, Emory University School of Medicine.; Winship Cancer Institute of Emory University.
Alemozaffar M; Department of Urology, Emory University School of Medicine, Atlanta, GA.
Schuster DM; From the Departments of Radiology and Imaging Sciences.; Pokaż więcej
Źródło :: Clinical nuclear medicine [Clin Nucl Med] 2020 Dec; Vol. 45 (12), pp. e525-e527.
Typ publikacji :: Case Reports; Journal Article
MeSH Terms :: Carboxylic Acids*
Cyclobutanes*
Incidental Findings*
Positron Emission Tomography Computed Tomography*
Adenocarcinoma of Lung/*diagnostic imaging
Mediastinum/*pathology
Prostatic Neoplasms/*diagnostic imaging
Adenocarcinoma of Lung/pathology ; Aged ; Biopsy ; Humans ; Male
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 11 11.

Tytuł :: Clustered Circulating Tumor Cells in Lung Adenocarcinoma: Implications of Test Results of Continuous Variables.
Autorzy :: Watanabe T; Department of General Thoracic Surgery, Nara Prefectural General Medical Center, Nara, Japan.; Department of Thoracic and Cardio-Vascular Surgery, Nara Medical University School of Medicine, Kashihara, Japan.
Sawabata N; Department of Thoracic and Cardio-Vascular Surgery, Nara Medical University School of Medicine, Kashihara, Japan .; Department of General Thoracic Surgery, JCHO Hoshigaoka Medical Center, Osaka, Japan .
Kawaguchi T; Department of Thoracic and Cardio-Vascular Surgery, Nara Medical University School of Medicine, Kashihara, Japan.
Yoshikawa D; Department of Thoracic and Cardio-Vascular Surgery, Nara Medical University School of Medicine, Kashihara, Japan.
Kushibe K; Department of General Thoracic Surgery, Nara Prefectural General Medical Center, Nara, Japan.
Nakane S; Department of General Thoracic Surgery, JCHO Hoshigaoka Medical Center, Osaka, Japan.
Taniguchi S; Department of Thoracic and Cardio-Vascular Surgery, Nara Medical University School of Medicine, Kashihara, Japan.; Pokaż więcej
Źródło :: Anticancer research [Anticancer Res] 2020 Dec; Vol. 40 (12), pp. 7089-7094.
Typ publikacji :: Case Reports; Journal Article
MeSH Terms :: Adenocarcinoma of Lung/*metabolism
Neoplastic Cells, Circulating/*metabolism
Adenocarcinoma of Lung/pathology ; Aged ; Humans ; Male ; Prognosis
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 12 12.

Tytuł :: Screening of Methylation Gene Sites as Prognostic Signature in Lung Adenocarcinoma.
Autorzy :: Dong M; Pulmonology Respiratory and Critical Care Unit, Gansu Province Hospital of Traditional Chinese Medicine, Lanzhou, China.
Yang Z; Infectious Diseases Unit, First People's Hospital of Guannan County, Guannan, China.
Li X; Pulmonology Respiratory and Critical Care Unit, Gansu Province Hospital of Traditional Chinese Medicine, Lanzhou, China.
Zhang Z; Orthopedics, Lanzhou Traditional Chinese Medicine Hospital, Lanzhou, China.
Yin A; Department of General Medicine, Affiliated Hospital of Yangzhou University, Yangzhou, China. .; Pokaż więcej
Źródło :: Yonsei medical journal [Yonsei Med J] 2020 Dec; Vol. 61 (12), pp. 1013-1023.
Typ publikacji :: Journal Article
MeSH Terms :: Adenocarcinoma of Lung/*genetics
DNA Methylation/*genetics
Gene Expression Regulation, Neoplastic/*genetics
Lung Neoplasms/*genetics
Mass Screening/*methods
Adenocarcinoma of Lung/pathology ; Adult ; Aged ; Aged, 80 and over ; Biomarkers ; Biomarkers, Tumor/genetics ; Female ; Genes ; Genes, Neoplasm/genetics ; Humans ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Prognosis ; Proportional Hazards Models
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 13 13.

Tytuł :: Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.
Autorzy :: Wang F; Department of Oncology, the Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Nangang District, 150086, Harbin, Heilongjiang, People's Republic of China.
Zhao N; Department of Oncology, the Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Nangang District, 150086, Harbin, Heilongjiang, People's Republic of China.
Gao G; Department of Thoracic Oncology, Cancer Center, West China Hospital, Chengdu, 610041, Sichuan Province, People's Republic of China.
Deng HB; Dental Hospital, The First Affiliated Hospital of Harbin Medical University, 23 Youzheng Road, Nangang District, 150001, Harbin, Heilongjiang, People's Republic of China.
Wang ZH; Department of Oncology, the Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Nangang District, 150086, Harbin, Heilongjiang, People's Republic of China.
Deng LL; Department of Oncology, the Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Nangang District, 150086, Harbin, Heilongjiang, People's Republic of China. .
Yang Y; Department of Oncology, the Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Nangang District, 150086, Harbin, Heilongjiang, People's Republic of China. .
Lu C; Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, People's Republic of China. .; Pokaż więcej
Źródło :: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2020 Nov; Vol. 146 (11), pp. 2851-2859. Date of Electronic Publication: 2020 Aug 02.
Typ publikacji :: Journal Article
MeSH Terms :: Adenocarcinoma of Lung/*genetics
Lung Neoplasms/*genetics
Tumor Suppressor Protein p53/*genetics
Adenocarcinoma of Lung/mortality ; Adult ; Aged ; Aged, 80 and over ; ErbB Receptors/genetics ; Female ; Genes, erbB-1 ; Humans ; Lung Neoplasms/mortality ; Male ; Middle Aged ; Mutation ; Prognosis ; Retrospective Studies ; Survival Analysis
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 14 14.

Tytuł :: A novel lncRNA, loc107985872, promotes lung adenocarcinoma progression via the notch1 signaling pathway with exposure to traffic-originated PM2.5 organic extract.
Autorzy :: Guo H; School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, PR China.
Feng Y; School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, PR China.
Yu H; School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, PR China.
Xie Y; School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, PR China.
Luo F; School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, PR China. Electronic address: .
Wang Y; School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, PR China; The Ninth People's Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, PR China. Electronic address: .; Pokaż więcej
Źródło :: Environmental pollution (Barking, Essex : 1987) [Environ Pollut] 2020 Nov; Vol. 266 (Pt 1), pp. 115307. Date of Electronic Publication: 2020 Aug 15.
Typ publikacji :: Journal Article
MeSH Terms :: Adenocarcinoma of Lung*
Lung Neoplasms*
RNA, Long Noncoding*
Cell Line, Tumor ; China ; Epithelial-Mesenchymal Transition ; Humans ; Particulate Matter ; Plant Extracts ; Receptor, Notch1 ; Signal Transduction
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 15 15.

Tytuł :: Surgically Resected Second Primary Lung Adenocarcinoma After Pembrolizumab Administration.
Autorzy :: Takamori S; Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Matsubara T; Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Haratake N; Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Miura N; Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Yamaguchi M; Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Toyozawa R; Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Seto T; Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Taguchi K; Cancer Pathology Laboratory, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Takenoyama M; Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan. Electronic address: .; Pokaż więcej
Źródło :: The Annals of thoracic surgery [Ann Thorac Surg] 2020 Nov; Vol. 110 (5), pp. e377-e379. Date of Electronic Publication: 2020 Apr 24.
Typ publikacji :: Case Reports
MeSH Terms :: Pneumonectomy*
Adenocarcinoma of Lung/*surgery
Antibodies, Monoclonal, Humanized/*therapeutic use
Lung Neoplasms/*surgery
Neoplasms, Second Primary/*surgery
Adenocarcinoma of Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/surgery ; Female ; Humans ; Lung Neoplasms/drug therapy ; Middle Aged
: Raport

Szczegóły

Skocz do pozycji: 16 16.

Tytuł :: T-type calcium channel antagonist, TTA-A2 exhibits anti-cancer properties in 3D spheroids of A549, a lung adenocarcinoma cell line.
Autorzy :: Kumari N; Department of Biomedical Engineering, Indian Institute of Technology Hyderabad, Telangana, India; Department of Biotechnology, Indian Institute of Technology Hyderabad, Telangana, India.
Bhargava A; Department of Biotechnology, Indian Institute of Technology Hyderabad, Telangana, India.
Rath SN; Department of Biomedical Engineering, Indian Institute of Technology Hyderabad, Telangana, India. Electronic address: .; Pokaż więcej
Źródło :: Life sciences [Life Sci] 2020 Nov 01; Vol. 260, pp. 118291. Date of Electronic Publication: 2020 Aug 15.
Typ publikacji :: Journal Article
MeSH Terms :: Antineoplastic Agents*
Adenocarcinoma of Lung/*pathology
Benzeneacetamides/*pharmacology
Calcium Channel Blockers/*pharmacology
Calcium Channels, T-Type/*drug effects
Lung Neoplasms/*pathology
Pyridines/*pharmacology
A549 Cells ; Adenocarcinoma of Lung/drug therapy ; Benzeneacetamides/therapeutic use ; Calcium Channels, T-Type/physiology ; Cell Movement/drug effects ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; HEK293 Cells ; Humans ; Lung Neoplasms/drug therapy ; Neoplasm Invasiveness/prevention & control ; Pyridines/therapeutic use
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 17 17.

Tytuł :: Diagnosis of Invasive Lung Adenocarcinoma Based on Chest CT Radiomic Features of Part-Solid Pulmonary Nodules: A Multicenter Study.
Autorzy :: Wu G; From the Departments of Precision Medicine (G.W., H.C.W., T.R., S.S., I.A., R.T.H.L., P.L.) and Radiology and Nuclear Medicine (H.C.W., I.A., P.L.), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Radiology, Affiliated Zhongshan Hospital of Dalian University, 6 Jiefang Street, Dalian 116001, People's Republic of China (G.W., J.S., J.W.); Department of Radiology, The Fifth Hospital of Dalian, Dalian, People's Republic of China (R.W.); and Department of Radiology, The Second Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China (J.X., J.B.).
Woodruff HC; From the Departments of Precision Medicine (G.W., H.C.W., T.R., S.S., I.A., R.T.H.L., P.L.) and Radiology and Nuclear Medicine (H.C.W., I.A., P.L.), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Radiology, Affiliated Zhongshan Hospital of Dalian University, 6 Jiefang Street, Dalian 116001, People's Republic of China (G.W., J.S., J.W.); Department of Radiology, The Fifth Hospital of Dalian, Dalian, People's Republic of China (R.W.); and Department of Radiology, The Second Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China (J.X., J.B.).
Shen J; From the Departments of Precision Medicine (G.W., H.C.W., T.R., S.S., I.A., R.T.H.L., P.L.) and Radiology and Nuclear Medicine (H.C.W., I.A., P.L.), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Radiology, Affiliated Zhongshan Hospital of Dalian University, 6 Jiefang Street, Dalian 116001, People's Republic of China (G.W., J.S., J.W.); Department of Radiology, The Fifth Hospital of Dalian, Dalian, People's Republic of China (R.W.); and Department of Radiology, The Second Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China (J.X., J.B.).
Refaee T; From the Departments of Precision Medicine (G.W., H.C.W., T.R., S.S., I.A., R.T.H.L., P.L.) and Radiology and Nuclear Medicine (H.C.W., I.A., P.L.), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Radiology, Affiliated Zhongshan Hospital of Dalian University, 6 Jiefang Street, Dalian 116001, People's Republic of China (G.W., J.S., J.W.); Department of Radiology, The Fifth Hospital of Dalian, Dalian, People's Republic of China (R.W.); and Department of Radiology, The Second Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China (J.X., J.B.).
Sanduleanu S; From the Departments of Precision Medicine (G.W., H.C.W., T.R., S.S., I.A., R.T.H.L., P.L.) and Radiology and Nuclear Medicine (H.C.W., I.A., P.L.), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Radiology, Affiliated Zhongshan Hospital of Dalian University, 6 Jiefang Street, Dalian 116001, People's Republic of China (G.W., J.S., J.W.); Department of Radiology, The Fifth Hospital of Dalian, Dalian, People's Republic of China (R.W.); and Department of Radiology, The Second Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China (J.X., J.B.).
Ibrahim A; From the Departments of Precision Medicine (G.W., H.C.W., T.R., S.S., I.A., R.T.H.L., P.L.) and Radiology and Nuclear Medicine (H.C.W., I.A., P.L.), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Radiology, Affiliated Zhongshan Hospital of Dalian University, 6 Jiefang Street, Dalian 116001, People's Republic of China (G.W., J.S., J.W.); Department of Radiology, The Fifth Hospital of Dalian, Dalian, People's Republic of China (R.W.); and Department of Radiology, The Second Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China (J.X., J.B.).
Leijenaar RTH; From the Departments of Precision Medicine (G.W., H.C.W., T.R., S.S., I.A., R.T.H.L., P.L.) and Radiology and Nuclear Medicine (H.C.W., I.A., P.L.), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Radiology, Affiliated Zhongshan Hospital of Dalian University, 6 Jiefang Street, Dalian 116001, People's Republic of China (G.W., J.S., J.W.); Department of Radiology, The Fifth Hospital of Dalian, Dalian, People's Republic of China (R.W.); and Department of Radiology, The Second Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China (J.X., J.B.).
Wang R; From the Departments of Precision Medicine (G.W., H.C.W., T.R., S.S., I.A., R.T.H.L., P.L.) and Radiology and Nuclear Medicine (H.C.W., I.A., P.L.), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Radiology, Affiliated Zhongshan Hospital of Dalian University, 6 Jiefang Street, Dalian 116001, People's Republic of China (G.W., J.S., J.W.); Department of Radiology, The Fifth Hospital of Dalian, Dalian, People's Republic of China (R.W.); and Department of Radiology, The Second Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China (J.X., J.B.).
Xiong J; From the Departments of Precision Medicine (G.W., H.C.W., T.R., S.S., I.A., R.T.H.L., P.L.) and Radiology and Nuclear Medicine (H.C.W., I.A., P.L.), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Radiology, Affiliated Zhongshan Hospital of Dalian University, 6 Jiefang Street, Dalian 116001, People's Republic of China (G.W., J.S., J.W.); Department of Radiology, The Fifth Hospital of Dalian, Dalian, People's Republic of China (R.W.); and Department of Radiology, The Second Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China (J.X., J.B.).
Bian J; From the Departments of Precision Medicine (G.W., H.C.W., T.R., S.S., I.A., R.T.H.L., P.L.) and Radiology and Nuclear Medicine (H.C.W., I.A., P.L.), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Radiology, Affiliated Zhongshan Hospital of Dalian University, 6 Jiefang Street, Dalian 116001, People's Republic of China (G.W., J.S., J.W.); Department of Radiology, The Fifth Hospital of Dalian, Dalian, People's Republic of China (R.W.); and Department of Radiology, The Second Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China (J.X., J.B.).
Wu J; From the Departments of Precision Medicine (G.W., H.C.W., T.R., S.S., I.A., R.T.H.L., P.L.) and Radiology and Nuclear Medicine (H.C.W., I.A., P.L.), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Radiology, Affiliated Zhongshan Hospital of Dalian University, 6 Jiefang Street, Dalian 116001, People's Republic of China (G.W., J.S., J.W.); Department of Radiology, The Fifth Hospital of Dalian, Dalian, People's Republic of China (R.W.); and Department of Radiology, The Second Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China (J.X., J.B.).
Lambin P; From the Departments of Precision Medicine (G.W., H.C.W., T.R., S.S., I.A., R.T.H.L., P.L.) and Radiology and Nuclear Medicine (H.C.W., I.A., P.L.), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Radiology, Affiliated Zhongshan Hospital of Dalian University, 6 Jiefang Street, Dalian 116001, People's Republic of China (G.W., J.S., J.W.); Department of Radiology, The Fifth Hospital of Dalian, Dalian, People's Republic of China (R.W.); and Department of Radiology, The Second Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China (J.X., J.B.).; Pokaż więcej
Źródło :: Radiology [Radiology] 2020 Nov; Vol. 297 (2), pp. 451-458. Date of Electronic Publication: 2020 Aug 25.
Typ publikacji :: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :: Tomography, X-Ray Computed*
Adenocarcinoma of Lung/*diagnostic imaging
Lung Neoplasms/*diagnostic imaging
Neoplasm Invasiveness/*diagnostic imaging
Solitary Pulmonary Nodule/*diagnostic imaging
Adenocarcinoma of Lung/pathology ; Aged ; Female ; Humans ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Invasiveness/pathology ; Retrospective Studies ; Solitary Pulmonary Nodule/pathology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 18 18.

Tytuł :: Lung adenocarcinoma in a patient with Li-Fraumeni syndrome bearing a novel germ-line mutation, TP53R333Vfs*12.
Autorzy :: Takahashi S; Department of Clinical Oncology, Akita University, Akita, Japan.
Shimazu K; Department of Clinical Oncology, Akita University, Akita, Japan.
Kodama K; Department of Pediatrics, Akita University, Akita, Japan.
Fukuda K; Department of Clinical Oncology, Akita University, Akita, Japan.
Yoshida T; Department of Clinical Oncology, Akita University, Akita, Japan.
Taguchi D; Department of Clinical Oncology, Akita University, Akita, Japan.
Takahashi T; Department of Pediatrics, Akita University, Akita, Japan.
Nanjyo H; Department of Pathology, Akita University Hospital, Akita, Japan.
Shibata H; Department of Clinical Oncology, Akita University, Akita, Japan.; Pokaż więcej
Źródło :: Japanese journal of clinical oncology [Jpn J Clin Oncol] 2020 Sep 28; Vol. 50 (10), pp. 1214-1217.
Typ publikacji :: Case Reports; Journal Article
MeSH Terms :: Adenocarcinoma of Lung/*complications
Adenocarcinoma of Lung/*genetics
Germ-Line Mutation/*genetics
Li-Fraumeni Syndrome/*complications
Lung Neoplasms/*complications
Lung Neoplasms/*genetics
Tumor Suppressor Protein p53/*genetics
Acrylamides/therapeutic use ; Adenocarcinoma of Lung/diagnostic imaging ; Adenocarcinoma of Lung/pathology ; Adult ; Aniline Compounds/therapeutic use ; Bone Neoplasms/secondary ; Female ; Gefitinib/therapeutic use ; Humans ; Li-Fraumeni Syndrome/drug therapy ; Li-Fraumeni Syndrome/genetics ; Lung Neoplasms/diagnostic imaging ; Lung Neoplasms/pathology ; Male ; Pedigree ; Protein Kinase Inhibitors/therapeutic use
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 19 19.

Tytuł :: Iodine-125 radioactive particles antagonize hyperprogressive disease following immunotherapy: A case report.
Autorzy :: Yang N; Tumor Research and Therapy Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University.
Zhang PL; Internal Medicine Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Liu ZJ; Internal Medicine Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.; Pokaż więcej
Źródło :: Medicine [Medicine (Baltimore)] 2020 Oct 30; Vol. 99 (44), pp. e22933.
Typ publikacji :: Case Reports; Journal Article
MeSH Terms :: Adenocarcinoma of Lung/*radiotherapy
Antineoplastic Agents, Immunological/*therapeutic use
Bevacizumab/*therapeutic use
Immunotherapy/*methods
Iodine Radioisotopes/*therapeutic use
Lung Neoplasms/*radiotherapy
Adenocarcinoma of Lung/diagnostic imaging ; Adenocarcinoma of Lung/drug therapy ; Adenocarcinoma of Lung/pathology ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bevacizumab/administration & dosage ; Combined Modality Therapy ; Disease Progression ; Humans ; Lung Neoplasms/diagnostic imaging ; Lung Neoplasms/drug therapy ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Tomography, X-Ray Computed
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 20 20.

Tytuł :: Intravenous analgesia with ultra-high-dose morphine for the treatment of headache and successful withdrawal of morphine: A case report and literature review.
Autorzy :: Zhang X; Department of Oncology, Changzhi People's Hospital.
Zhang J; Department of Anesthesiology, Changzhi People's Hospital.
Du Y; Department of Oncology, Changzhi People's Hospital.
Wang M; Department of Oncology, Changzhi People's Hospital.
Gao Y; Department of Oncology, Changzhi People's Hospital.
Zhou L; Quality Control Department, Changzhi People's Hospital, Changzhi, Shanxi.
Lu J; Department of Pathophysiology, College of Basic Medical Sciences, Zhengzhou University.; Collaborative Innovation Center of Henan Province for Cancer Chemoprevention, Zhengzhou, Henan, China.
Zhao J; Department of Oncology, Changzhi People's Hospital.; Pokaż więcej
Źródło :: Medicine [Medicine (Baltimore)] 2020 Oct 30; Vol. 99 (44), pp. e22919.
Typ publikacji :: Case Reports; Journal Article; Review
MeSH Terms :: Adenocarcinoma of Lung*/pathology
Adenocarcinoma of Lung*/therapy
Cancer Pain*/diagnosis
Cancer Pain*/drug therapy
Headache*/diagnosis
Headache*/drug therapy
Headache*/etiology
Lung Neoplasms*/pathology
Lung Neoplasms*/therapy
Meningeal Neoplasms*/physiopathology
Meningeal Neoplasms*/secondary
Meningeal Neoplasms*/therapy
Pain Management/*methods
Administration, Intravenous ; Adult ; Analgesics, Opioid/administration & dosage ; Dose-Response Relationship, Drug ; Female ; Humans ; Morphine/administration & dosage ; Pain Measurement ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Informacja

Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Adenocarcinoma of Lung"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język